Cancer Genetics, Inc. (CGIX) News

Cancer Genetics, Inc. (CGIX)

Today's Latest Price: $3.12 USD

0.23 (7.96%)

Updated Aug 7 3:59pm

Add CGIX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

Filter CGIX News Items

CGIX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest CGIX News From Around the Web

Below are the latest news stories about Cancer Genetics Inc that investors may wish to consider to help them evaluate CGIX as an investment opportunity.

Cancer Genetics reports Q1 results

Cancer Genetics (CGIX): Q1 GAAP EPS of -$0.56.Revenue of $1.43M (-21.4% Y/Y)Cash and cash equivalents of ~$3.9M.Press Release...

Seeking Alpha | June 24, 2020

Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates

RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical…

GlobeNewswire | June 24, 2020

Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates

RUTHERFORD, N.J., June 01, 2020 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.

Yahoo | June 1, 2020

Cancer Genetics Issues Letter to Shareholders

RUTHERFORD, N.J., Feb. 20, 2020 -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and.

Yahoo | February 20, 2020

Introducing Cancer Genetics (NASDAQ:CGIX), The Stock That Collapsed 98%

Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. For example, we sympathize with...

Yahoo | November 14, 2019

Cancer Genetics Announces 1-for-30 Reverse Stock Split

Cancer Genetics, Inc. (CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. The reverse stock split is intended to increase the per share trading price of Cancer Genetics

ACI Information Group | October 24, 2019

Cancer Genetics, Inc. Announces Strategic Transactions

Cancer Genetics, Inc. (CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions. As the result of the previously announced sale of the company’s BioPharma business to Interpace Diagnostics Group, Inc. (IDXG) or its affiliate, IDXG or its affiliate paid approximately $6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately $7.7 million due to CGIX.

Yahoo | October 24, 2019

Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019.

Yahoo | October 17, 2019

The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRN...

Benzinga | August 28, 2019

The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unit...

Benzinga | August 27, 2019






Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5998 seconds.